International Biotechnology Trust’s Protagonist Therapeutics PTGX Stock Holding History

International Biotechnology Trust’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$332K	Hold	19,900	–	–	0.11%	64
2023 Q2	$549K	Buy	+19,900	New	+$498K	0.17%	55
2022 Q3	–	Sell	-128	Closed	-$16.2K	–	78
2022 Q2	$16.2K	Buy	+128	New	+$1.55K	0.17%	69
2021 Q3	–	Sell	-152,000	Closed	-$6.81M	–	73
2021 Q2	$6.81M	Hold	152,000	–	–	1.8%	18
2021 Q1	$3.94M	Hold	152,000	–	–	1.04%	25
2020 Q4	$3.06M	Hold	152,000	–	–	0.84%	25
2020 Q3	$2.97M	Buy	+152,000	New	+$2.85M	0.96%	25

Other funds holding PTGX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

International Biotechnology Trust's PTGX Position: Q3 2023 in Review

International Biotechnology Trust held its Protagonist Therapeutics (PTGX) position steady in Q3 2023 at 19,900 shares worth $332K. The position accounts for 0.11% of the portfolio, ranked #64.

International Biotechnology Trust first reported a position in PTGX in Q3 2020 and has held it in 7 quarters since. The position peaked at $6.81M in Q2 2021. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

International Biotechnology Trust held 19,900 shares of Protagonist Therapeutics worth $332K as of Q3 2023.
International Biotechnology Trust left its Protagonist Therapeutics share count unchanged in Q3 2023.
Protagonist Therapeutics made up 0.11% of International Biotechnology Trust's portfolio in Q3 2023, its #64 holding.
International Biotechnology Trust first reported a position in Protagonist Therapeutics in Q3 2020 and has held it in 7 quarters since.
International Biotechnology Trust's Protagonist Therapeutics position peaked at $6.81M in Q2 2021.
144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.